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Renal accumulation of streptavidin: Potential use for targeted therapy
to the kidney. Streptavidin exhibits a remarkable accumulation in the
kidney. Biodistribution studies with radio-iodinated streptavidin showed
that 70 to 80% of the injected dose per gram tissue (%/g) were retained
in kidneys of Balb/C mice for three to four days compared to less than
5 %/g levels in other tissues. This observation means that 15 to 20% of the
injected dose is accumulated in the kidney, an organ that constitutes less
than 1% of total body weight. Similar results of percent radioactivity per
total kidney were obtained in other mouse strains as well as in rats and
rabbits. Avidin, or the post-secretory form of streptavidin which is of a
higher molecular weight, do not show any preferential affinity to the
kidney. The kidney-accumulated streptavidin was mostly confined to the
cortex, concentrated in the proximal tubular cells. Accumulation of
streptavidin in the kidney was independent of biotin, since addition of
biotin to radio-iodinated streptavidin prior to injection did not affect its
kidney uptake. Therefore, streptavidin, which aquires its kidney accumu-
lation property following truncation of the native form, may be utilized for
renal specific delivery of chemotherapeutic agents, radioactive isotopes
and other effector molecules. Such ligands can be linked to streptavidin via
conventional coupling methods or following their biotinylation. Prelimi-
nary experiments showed that streptavidin can target to the kidney
biotinylated ligands or high doses of chemically linked radionuclides.
Streptavidin is a 58 kDa non-glycosylated neutral protein of
Streptomyces avidinii, which displays a remarkably strong binding
affinity (1015 M') for the vitamin biotin [1]. This protein is similar
in structure and biotin-binding properties to its counterpart,
avidin, a positively charged egg-white glycoprotein [2]. Both
proteins are tetramers containing one biotin-binding site per
subunit. The streptavidin- or avidin-biotin complexes have pro-
vided extremely useful and versatile intermediates in a variety of
biological and analytical systems [3, 4]. Avidin or streptavidin,
either in their native form, or when coupled to various reporter
probes such as fluorescent dyes, radioactive elements, enzymes or
immobilized matrices, can recognize biotin coupled to various low
or high molecular weight substances. More recently, the use of
these two systems has been extended to in vivo procedures for
cancer diagnosis and treatment such as radioimmunodetection
[5—8] and drug immunotargeting [9, 10]. Radiolabeled or drug-
bound avidin could be targeted to biotinylated antibodies concen-
trated at the tumor site.
Nonetheless, avidin and streptavidin are distinct and differ from
each other, as evidenced by their lack of immunological cross-
reactivity, remote evolutionary origin and differences in charge
and glycosylation. Despite some similarity in a series of short
interrupted segments, the amino acid composition and primary
sequence are also different [11]. The comparison between these
two proteins has recently been extended by us to include their in
vivo distribution pattern upon intravenous (i.v.) administration
[12]. Biodistribution studies performed with radio-iodinated avi-
din showed a relatively rapid clearance, with only residual levels in
blood and most organs, including the kidney, already at six hours
after injection.
Biodistribution of streptavidin was found to be dependent on a
truncation process occurring during its purification. Recent stud-
ies have shown that the post-secretory form of streptavidin is
larger than the currently used form. Upon certain isolation
procedures the 18 kDa subunit of the post-secretory streptavidin
may undergo proteolytic degradation to give a truncated form of
a molecular size of about 14 kDa [13]. The truncation is effected
through the cleavage of 12 to 14 amino acid residues at the
N-terminal and up to 18 residues at the C-terminal end of each
subunit. Whereas the 18 kDa streptavidin subunit was found to be
sensitive to the action of several commercially available proteo-
lytic enzymes, the truncated form exhibits a remarkable resistance
to any proteolytic activity [14]. Biodistribution studies in mice
performed with the intact post-secretory form of streptavidin
showed a normal rate of protein clearance, with levels of 20%/g in
blood at six hours and 2 to 12%/g in blood and tissues at 24 hr (a
pattern similar to most proteins). On the other hand, the trun-
cated form of streptavidin (most commercial preparations) had
low blood and tissue levels, but its kidney uptake was exception-
ally high [12].
In the present study we extended the investigation on the
selective uptake of streptavidin (the commercial truncated form)
by the kidney, referring to parameters such as the effect of time on
the accumulation and clearance patterns of streptavidin, occur-
rence of this phenomenon in other animal species, localization
region of streptavidin in the kidney, effect of biotin on kidney
uptake, and the potential use of streptavidin as a targeting device
to the kidney.
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Materials. Post-secretory streptavidin, provided by E. Bayer and
H. Ben-Hur, was purified from the spent culture broth of Strep-
tomyces avidinii using a modified iminobiotin-containing affinity
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Fig. 1. Biodistribution of '251-streptavidin.
Comparison between native (intact, i.v.) and
truncated (iv. and i.p.) streptavidin at 24 hours
following injection was performed in pairs of
Balb/C mice (1 to 2 j.g protein, 1 sCi/mouse).
Data are mean percent of injected radioactivity
dose/gram tissue so. Abbreviations are: K,
kidney; S, spleen; L, liver; H, heart; Lu, lung;
M, muscle; B, bone; BI, blood.
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Fig. 2. Biodistrihution of '251.streptavidin (truncated) at different time intervals following iv. injection into pairs of BalbIc mice. Legends and data are as
in Figure 1.
column [13]. Streptavidin was provided as a gift by Boehringer-
Mannheim GmbH (Mannheim, Germany). Biotinyl-tyrosine
(b-Y) was prepared by reacting biotin-N-hydroxysuccinimide (355
mg) dissolved in 2 ml DMF with tyrosine (269 mg) in 2 ml of 1 M
NaOH. After 24 hours at room temperature the solvents were
evaporated and the b-Y was radioiodinated. Biotinyl-alanyl-ala-
nyl-tyrosine (b-AAY) was similarly prepared by reacting biotin-
N-hydroxysuccinimide with AAY (the same molar ratio). Biotinyl-
cs-melanotropin hormone (b-aa-MSH) was provided by Dr. Y.
Salomon. Radioactive iodine, 25I or 131J was purchased from
Amersham International plc. (Buckinghamshire UK).
Radiolabeling. Radiolabeling of tyrosine residues in proteins
with 1251 or 131j was performed by the Chloramine-T method [15].
Protein (0.2 ml of I mg/mI) in 0.02 M sodium phosphate buffer
pH 8 was reacted with 0.5 mCi or 2.5 mCi of Na1251 or Na'31 I in
the presence of Chloramine-T (10 pJ of 2 mg/ml). After two
minutes at room temperature the reaction was terminated by
adding sodium metabisulfite (10 sl of 2 mg/mI). The radiolabeled
proteins were purified by gel exclusion chromatography on
Sepharose G-25 (Pharmacia Fine Chemicals, Piscataway, NJ;
USA). Radio-iodinated b-Y, b-AAY (20 tg) and b-a-MSH (1.5
mg) similarly prepared were complexed to 0.2 mg streptavidin (30
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Biodistribution and pre-targeting studies
In biodistribution experiments, age- (10 to 12 weeks), sex- and
weight-matched Balb/c mice were given i.v. injections, into the
lateral tail vein, of the radio-iodinated proteins or radio-iodinated
biotinyl-derivatives complexed to streptavidin (1 j.tCi/mouse). At
time intervals as indicated below, blood samples were withdrawn
from the tail, mice were killed and organs were dissected out.
Organs were washed in phosphate buffered saline (PBS), blotted
dry, weighed and counted for radioactivity. The results are
expressed as mean percentage of injected radioactivity dose per
gram tissue (%/g), or per whole organ. Biodistribution of 1251..
streptavidin in a rat or a rabbit was performed following injection
into the tail or ear vein, respectively, of radio-iodinated strepta-
vidin (6 to 7 Ci/animal). After 24 hours, blood was withdrawn,
the animals were killed, and tissues and organs were analyzed as
described above.
In experiments designed to evaluate the capacity of streptavidin
to target therapeutic doses of 1251 and 1311 athymic nude mice
were injected with the radio-iodinated derivatives (0.1 mCi!
mouse). 125j and '311-labeled bovine serum albumin (BSA) prep-
arations were used as control. External radioactivity was moni-
tored daily at a distance of 5 mm from the kidney or head region.
The results are expressed as the mean percentage of the decay in
radioactivity in comparison to day 0.
B
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Fig. 3. Quantitative retention of '251-streptavidin
1 in whole organs (A) or biodistribution of 125j
streptavidin (B) at 24 hours following injection
into a Balb/c mouse, Wistar rat and New Zealand
rabbit. Data are expressed as percent of injected
radioactivity dose/organ (A) or /gram tissue (B).
Symbols are: (U), kidney; (P4) spleen, (L)
liver; (B) heart; (LI) lung; (LI) muscle; (B)
blood.
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Fig. 4. Biodistriburion of a constant amount of '251-streptavidin (at 24 h)
mixed with increasing amounts of cold streptavidin prior to injection into a
Balblc mouse. Data are expressed as percent of injected radioactivity
dose/gram tissue or as g streptavidin/kidney. Symbols are: (0) radioac-
tivity dose; (X) streptavidin.
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Fig. 5. Biodistribution of '251-streptavidin in total
kidney (K), medulla (M) and cortex (C). Data
are expressed as percent of injected
radioactivity dose/gram tissue for a rabbit (B)
and mean percent of injected radioactivity dose/
gram tissue su for 3 mice (A).
Immunohistochemical staining
Mice were injected i.v. with 500 xg streptavidin and the kidneys
were removed 24 hours later. Staining was performed at room
temperature on 3 x frozen sections mounted on polylysine-coated
glass slides, fixed with 4% buffered formaldehyde (20 mm) and
rinsed with PBS. The sections were then treated with 5% BSAJ
PBS (15 mm) and anti-streptavidin antibody was applied (1 hr).
Endogenous peroxidase activity was blocked by incubating the
tissue with 3% H202 in ethanol (40 mm). The rinsed sections were
incubated with peroxidase-labeled goat-anti rabbit antibody (Bio-
Makor, Rehovot, Israel) at 1:100 dilution (1 hr) and peroxidase
was revealed with 0.02% 3-amino-9-ethylcarbazole (Bio-Makor)
and 0.02% H202 in 20 m acetate buffer (pH 5.2). The sections
were counterstained with Mayer's hematoxylin and mounted in
Kaiser's glycerol-gelatin (Sigma Diagnostics, St. Louis, MO,
USA). In control staining immune antibody was replaced by a
non-specific antibody.
Antibody. Anti-streptavidin antibody was prepared by multi-
focal intra-dermal immunizations of rabbits with 3 X 1 mg
streptavidin in complete Freund's adjuvant. The Ig fractions of
preimmune (control) and immune sera were used at 50 xg/ml.
Autoradiography of streptavidin-containing frozen rat kidney
sections (5 jx) was performed with kidneys obtained from rats 24
hours following the injection of 6 dxCi 25I-streptavidin. The
sections were mounted on glass slides, dried for 30 minutes and
apposed to radiation sensitive film (Hyperfilm-/3max, Amersham)
for one day. The film was developed using standard methods.
Results
Biodistribution of streptavidin
A comparison of the biodistribution of intact and truncated
streptavidin at 24 hours following i.v. injection of the radioiodi-
nated proteins into Balb/c mice is illustrated in Figure 1. As
shown, radioactivity levels of intact streptavidin in blood and
organs, including the kidney, was in the range of 2 to 10 %/g.
Levels of the truncated streptavidin in blood and most organs
were lower, with radioactivity values that did not exceed 4%/g,
except for the kidney. Accumulation in the kidney was exception-
ally high after both intravenous and intraperitoneal (i.p.) injec-
tions, with uptake levels ranging between 70 to 80%/g (around
15% per kidney). Addition of exogenous biotin did not affect the
accumulation pattern of truncated streptavidin (data not shown).
Kidney accumulation and clearance of radioactivity as a function
of time (Fig. 2) showed that already at two hours following i.v.
injection the level of radioactivity in the kidney was 22%/g,
increasing to more than 60%/g at 12 hours, peaking to 70%/g at 24
hours, and declining to 26%/g only at 86 hours. Radioactivity in
spleen, liver, heart, lung, muscle and bone did not exceed 6%/g
along this time period, except for blood radioactivity which was
13%/g at two hours but dropped to 2%/g after 24 hours. Biodis-
tribution experiments in rats and rabbits showed preferential
accumulation of streptavidin in the kidneys of these animal
species as well. Organ radioactivity values were similar to those
observed in mice and ranged between 13 and 17% per kidney (Fig.
3A). However, %/g levels were lower due to the larger size of the
organs, (Fig. 3B). Radioactivity levels in spleen, liver, heart, lung,
muscle and blood were low so that kidney/other tissue ratios, as
well as total kidney uptake in the three animal species were
comparable.
The total amounts of streptavidin injected in the experiments
described above were in the range of 0.5 to 2.0 xg protein per
mouse. A quantitative analysis of the kidney capacity to accumu-
late streptavidin was carried out by injecting a constant amount of
radioalabeled streptavidin mixed with increasing quantities of the
cold protein into mice. Assuming that radioactive and cold
streptavidin do not differ in their kidney accumulation properties,
the results presented in Figure 4 indicate that whereas 100 or 200
g cold streptavidin did not significantly affect '251-streptavidin
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Fig. 6. Immunohistochemical (immunoperoxidase) staining of streptavidin in kidney sections. Mouse kidneys were removed 24 hours following
streptavidin injection (500 g) and sections were stained with anti-streptavidin polyclonal antibody (immune Ig). A. Staining of streptavidin sequestered
in proximal tubules near capsule (indicated by arrows in A and C) using anti-streptavidin immune 1g. B. Negative staining of tubules with control
(pre-immune) 1g. C. Positive staining of tubules near the glomeruli and absence of staining in the glomeruli (A-C: 660x), D. Positive staining near
glomeruli at lower magnification (270X). E. Autoradiographic image of rat kidney sections (24 hr after 1251-streptavidin injection) showing strong
peripheral radioactivity (Xl).
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Fig. 7. Monitoring external radioactivity in athjmic nude mice following
'251-streptavidin or 1311-streptavidin injection. Athyiiic nude mice (7 mice!
group) were injected i.p. with 0.1 mCi of radioactive streptavidin and
monitoring was performed at the kidney (•) and head (0) regions.
'251-labeled BSA was used as control (A). Data are expressed as mean
radioactivity units SD.
accumulation in the kidney, 300.tg caused a reduction of 35% in
the radioactivity accumulated per gram of kidney tissue. Since
20% of the injected dose was retained in each kidney, it can be
calculated that at 24 hours after injecting 300 g streptavidin 40
ig of the protein were retained in each kidney.
Streptavidin distribution in kidney medulla and cortex
To examine, whether streptavidin accumulation in the kidney is
confined to restricted regions, mice were injected with 1251
streptavidin and at set time intervals their kidneys were removed,
counted for total radioactivity and dissected under a microscope
into the cortex and medulla sections (Fig. 5). Values in terms of
%/g tissue for total kidney, medulla and cortbx were 76, 43 and 92
at 24 hours and 57, 37 and 97 at 48 hours, respectively, indicating
preferential accumulation in the cortex. A more accurate evalua-
tion of cortex and medulla distribution could be obtained in the
rabbit (at 24 hr), with values for kidney, medulla and cortex of 2.3,
0.2 and 3.14 %Ig tissue, respectively (1.4%/g for intermediary
tissue).
Immunohistochemistiy
Immunoperoxidase staining of streptavidin in mouse renal
sections was carried out 24 hours following streptavidin injection
(Fig. 6). Staining with anti-streptavidin (polyclonal) antibody and
peroxidase-labeled goat anti-rabbit antibody revealed sequestra-
tion of streptavidin in proximal tubules mainly near the capsule.
Positively stained tubules could be found also around the glomer-
uli whereas the absence of staining in the glomeruli was evident.
Autoradiographic image of rat kidney sections (24 hr after
1251-streptavidin injection) showed strong peripheral radioactivity.
Use of streptavidin for targeting to the kidney
Preliminary experiments to estimate the ability of streptavidin
to target therapeutic doses of radionuclides were performed in
order to verify the anticipated high kidney/other tissue ratio.
These experiments were performed in athymic nude mice (which
will serve in the future as carriers of human-derived tumors in
pre-clinical experiments). Two streptavidin preparations radio-
iodinated with radioisotopes of different decaying dose rates, that
is, 125! or 131! (half-time 60 and 8 days, respectively, 0.1 mCi!
mouse), were administered i.p. into two groups of mice. 1251-BSA
was used as control. External radioactivity was monitored during
a period of several days at the kidney or head regions of the intact
mice. As is illustrated in Figure 7 top, 125j radioactivity persisted
in the kidney region for three days and declined gradually to 43%
on day 4 and to 37% on day 5. For comparison, radioactivity at the
head region declined to 17% of the original level already after one
day. Kidney radioactivity of 1251-BSA was low. 1311-streptavidin
(Fig. 7 bottom) persisted for a shorter period of time and was
down to 45% on day 2 and to 11% on day 4.
A preliminary study was designed to demonstrate the targeting
of biotinylated ligands via streptavidin. Biotinyl-tyrosine (b-Y),
biotinyl-alanyl-alanyl-tyrosine (b-AAY) and b-a-MSH (11 resi-
dues long peptide), radio-iodinated at their tyrosine residues,
were allowed to interact with cold streptavidin. The resulting
complexes were separated from free iodide or uncomplexed
1251-biotinyl-ligand by size exclusion chromatography. As shown
in Figure 8, radioactive b-Y and b-AAY preferentially accumu-
lated in the kidney, their biodistribution and time dependent
accumulation (Fig. 9) being comparable to that of 1251-streptavi-
din itself. Accumulation of b-a-MSH was short-lived, with 40%/g
at seven hours post-injection which declined to 15%/g at 24 and 48
hours (Figs. 8 and 9).
Discussion
The present study describes the specific accumulation of
streptavidin in the kidney and demonstrates its potential use as a
targeting vehicle to the kidney for specific renal delivery of
therapeutic agents. Streptavidin accumulates preferentially in the
kidney cortex and is retained there for a period of three to four
days. Uptake values recorded in different experiments with several
mouse strains as well as with two other animal species (rat and
rabbit) indicated that approximately 15% of the total injected
dose can be accumulated in each kidney, an organ which com-
prises only 1% of total body weight. In terms of protein capacity,
40 xg of the protein can be retained in a mouse kidney, a value
which is even higher in terms of tissue specificity since streptavidin
accumulation is confined to the kidney cortex. The high and
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prolonged kidney retention of streptavidin in comparison to the
low levels in blood and other organs provides exceptionally high
"target" to "non-target" ratios. Streptavidin may thus serve as a
drug carrier for site-specific delivery or release of radionuclides,
anti-viral or anti-inflammatory drugs, antibiotics, diuretics, che-
moterapeutic agents and other effector molecules. Specific target-
ing to the kidney may increase drug levels in this organ while
decreasing general toxicity and adverse side effects. Drug attached
to streptavidin via appropriate carrier molecules can be pro-
grammed for gradual and slow release as has been shown for
other macro-molecularized drug systems [16—21].
Streptavidin retention in the kidney could he due to interaction
with endogenous biotin (10 nM in mice and 2 n in human) [221,
or biotinyl-enzymes [231 that might have been enriched in the
kidney. However, addition of biotin to streptavidin prior to
injection did not significantly affect its biodistribution pattern.
Also, the observation that native streptavidin as well as avidin,
both displaying biotin-binding properties similar to that of strepta-
vidin, did not bind to the kidney, supports the assumption that
biotin or biotinyl groups do not serve as the major anchors for
streptavidin binding in the kidney. Thus, a major advantage of
streptavidin is that in addition to its high kidney accumulation, it
is also equipped with extremely efficient built-in binding sites for
biotin which are not required for its retention in the kidney. A
large variety of biotinylated ligands such as proteins (antibodies,
enzymes, cytokines), peptides, drugs, toxins, radionuclides, fluo-
rescent tags, etc. can be targeted to the kidney via streptavidin.
The biotin-ligand conjugate may be designed to permit sustained
release of the ligand by inclusion of appropriate cleavable or
dissociable chemical moieties between the biotin and the reactive
group, or else to ascertain a stable bond [4].
The high kidney uptake of streptavidin could be attributed to
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Fig. 8. Taigeting (biodistribution) of '251-b-Y,
'25Jby and 1251-b-n-MSH to the kidney
following their complexing to non-radioactive
streptavidin. Uncomplexed ligands were down to
1 to 2% at 2 hours following injection. Data for
pairs of mice are in Figure 1. Symbols are: (U)
kidney; () spleen; (EEl) liver; () heart; (El)
lung; (11) blood.
Fig. 9. Time dependent retention in the kidney of
(A) 1251-streptavidin (U), 1251-b-Y (VA) and (B)
'25JbaMSH complexed to non-radioactive
streptavidin. Data for pairs of mice are in
Figure 1.
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the enzyme resistance property of streptavidin, whether or not
interaction with specific sites is involved. Recent studies describe
cell-adsorptive properties of the streptavidin molecule indepen-
dent of biotin [24—26]. The binding, which is low in the native
form but is enhanced by truncation and biotin complexing,
appears to be linked to an RYD-containing sequence in strepta-
vidin. This sequence is highly homologous to the RGD domain of
fibronectin and other adhesion proteins which interact with cell
surface integrins [27—29]. Following interaction with endogenous
biotin, streptavidin may reach the kidney and interact with
cell-surface adhesion receptors via RGD mimicry.
Another mechanism could be related to the processing of low
molecular weight proteins (lower than 64 kDa) which are filtered
through the glomeruli and undergo a process of tubular endocy-
tosis and active lysosomal degradation [301. These proteins first
interact with specific sites of the luminal membrane and are
internalized by endocytic vacuoles. Proteolytic enzymes and acidic
pH accelerate their catabolism in the lysosomes, whereas mem-
brane transport systems are involved in the active secretion and
reabsorption of degradation products such as amino acids.
Streptavidin may belong to this category of proteins since immu-
nohistochemical staining of streptavidin-containing kidneys with
anti-streptavidin antibody indicated that streptavidin indeed ac-
cumulates in proximal tubular cells. Entrapment of streptavidin in
tubular cells following glomerular filtration may be due to its
enzyme resistance and delay in degradation. This protein, though
falling within the upper limit of the molecular size range, may
benefit from its tightly rigid structure which becomes even more
condensed upon interaction with endogenous biotin.
It has been suggested that such low molecular weight proteins
may serve as efficient drug carriers that release drugs site-
specifically in the kidneys upon catabolism [31]. Although this
type of drug targeting may be beneficial in certain cases, it is still
a short-term transient event manifested via a relatively rapid
uptake and degradation of the drug protein. The use of an
enzyme-resistant protein such as streptavidin, irrespective of its
renal accumulation mechanism, may offer certain advantages such
as longer maintenance of therapeutic or diagnostic ligands as well
as improved local kinetics of endorenally released drugs. Co-
valently bound radionuclides, which persists in the kidney for
three to four days, may be utilized for streptavidin-mediated
radiotherapy. Biotinylated ligands, on the other hand, may be
used for controlling drug releasability dependent on the length of
the spacer: a small directly bound ligand such as b-Y (where
tyrosine is radio-iodinated) accumulates exclusively in the kidney
and is gradually released due to eventual degradation of the
streptavidin-carrier. Even tyrosine spaced by two alanyl residues
in b-AAY is not easily degradable. This could be due to the tightly
structured pocket and relatively large cleft of the biotin-binding
site which may shield adjacent residues and protect them from
enzymatic cleavage. Introduction of longer spacers will release the
ligand at a faster rate as in the case of b-a-MSH (tyrosine is at
position 2 but possible biotinyl-lysine at position 11 forms a
7-residue long spacer). Availability of resistant or susceptible
intermediary linkers may enable tailor-made attachments of ii-
gands to streptavidin to provide high and prolonged organ
maintenance, or else enhanced release.
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